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In 2005, the International Committee of Medi-
cal Journal Editors (ICMJE) initiated a policy re-
quiring investigators to deposit information about 
trial design into an accepted clinical trials registry 
before the onset of patient enrollment (1). This 
policy aimed to ensure that information about the 
existence and design of clinically directive trials 
was publicly available, an ideal that leaders in evi-
dence-based medicine have advocated for decades 
(2). The policy precipitated much angst among re-
search investigators and sponsors, who feared that 
registration would be burdensome and would sti-
fle competition. Yet, the response to this policy has 
been overwhelming. The ICMJE promised to re-
evaluate the policy in 2 years after implementation. 
Here, we summarize that reevaluation, specifically 
commenting on registries that meet the policy re-
quirements, the types of studies that require reg-
istration, and the registration of trial results. As is 
always the case, the ICMJE establishes policy only 
for the 12 member journals (a detailed description 
of the ICMJE and its purpose is available at www.
icmje.org), but many other journals have adopted 
our initial trial registration recommendations, and 
we hope that they will also adopt the modifications 
discussed in this update.
The research community has embraced tri-
al registration. Before the ICMJE policy, Clinical-
Trials.gov, the largest trial registry at the time, con-
tained 13 153 trials; this number climbed to 22 714 
one month after the policy went into effect (3). In 
April 2007, the registry contained over 40 000 tri-
als, with more than 200 new trial registrations oc-
curring weekly (Zarin D, personal communica-
tion). The 4 other registries that meet the ICMJE 
criteria have also grown as scores of journals have 
adopted the ICMJE clinical trials registration pol-
icy. In response to burgeoning registration, many 
investigators, sponsors, and government agen-
cies have asked the ICMJE to recognize their local 
registries as databases that meet the policy. Fortu-
nately, the World Health Organization’s (WHO) 
International Clinical Trial Registry Platform (IC-
TRP), which was nascent when the ICMJE began 
Clinical Trial Registration: Looking Back and Moving Ahead
Editorial
Key Summary Points
In addition to accepting registration in any of the 5 existing 
registries, the ICMJE will accept registration of clinical 
trials in any of the primary registers that participate in the 
WHO ICTRP. Registration in a partner register only is 
insufficient.
The ICMJE will begin to implement the WHO definition 
of clinical trials for all trials that begin enrollment on or 
after 1 July 2008. This definition states that a clinical trial 
is “any research study that prospectively assigns human 
participants or groups of humans to one or more health-
related interventions to evaluate the effects on health 
outcomes.”
The ICMJE will not consider results posted in the same 
clinical trials registry in which the primary registration 
resides to be previous publication if the results are 
presented in the form of a brief, structured (<500 words) 
abstract or table.
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to require trial registration, has matured rapidly 
and provides options for those that desire a wider 
array of registries. The ICTRP has taken the first 
steps toward developing a network of primary 
and partner registers that meet WHO-specified 
criteria (4). Primary registers are WHO-selected 
registers managed by not-for-profit entities that 
will accept registrations for any intervention-
al trials, delete duplicate entries from their own 
register, and provide data directly to the WHO. 
Partner registers, which will be more numerous, 
will include registers that submit data to primary 
registers but limit their own register to trials in a 
restricted area (such as a specific disease, compa-
ny, academic institution, or geographic region).
The ICMJE strongly supports the WHO’s 
efforts, through the ICTRP, to develop a coor-
dinated process for identifying, gathering, de-
duplicating, and searching trials from registries 
around the world, thus eventually providing a 1-
stop search portal for those seeking information 
about clinical trials. In addition to the 5 existing 
registries, the ICMJE will now also accept regis-
tration in any of the primary registers that partic-
ipate in the WHO ICTRP. Because it is critical 
that trial registries are independent of for-profit 
interests, the ICMJE policy requires registration 
in a WHO primary register rather than solely in 
a partner register, since for-profit entities manage 
some partner registers. As previously, trial regis-
tration with missing or uninformative fields for 
the minimum data elements is inadequate (1).
Initially, the ICMJE required registration of 
all clinically directive trials, which it defined as 
“any research project that prospectively assigns 
human subjects to intervention or comparison 
groups to study the cause-and-effect relation-
ship between a medical intervention and a health 
outcome” (1). In May 2005, the ICMJE clarified 
this definition to exclude preliminary trials de-
signed to study pharmacokinetics or major un-
known toxicity (phase I trials) (5). However, the 
ICMJE recognizes the potential benefit of hav-
ing information about preliminary trials in the 
public domain, because these studies can guide 
future research or signal safety concerns. Con-
sequently, the ICMJE is expanding the defini-
tion of the types of trials that must be registered 
to include these preliminary trials and adopts 
the WHO’s definition of clinical trial: “any re-
search study that prospectively assigns human 
participants or groups of humans to one or more 
health-related interventions to evaluate the ef-
fects on health outcomes” (4). Health-related 
interventions include any intervention used to 
modify a biomedical or health-related outcome 
(for example, drugs, surgical procedures, devic-
es, behavioral treatments, dietary interventions, 
and process-of-care changes). Health outcomes 
include any biomedical or health-related mea-
sures obtained in patients or participants, in-
cluding pharmacokinetic measures and adverse 
events. As previously, purely observational stud-
ies (those in which the assignment of the medical 
intervention is not at the discretion of the inves-
tigator) will not require registration. The ICMJE 
member journals will start to implement the ex-
panded definition of clinically directive trials for 
all trials that begin enrollment on or after 1 July 
2008. Those who are uncertain whether their tri-
al meets the expanded ICMJE definition should 
err on the side of registration if they wish to seek 
publication in an ICMJE journal.
Over the time during which registration of 
trial methods has become common practice, sev-
eral forces have begun advocating for registration 
of trial results. We recognize that the climate for 
results registration will probably change dramat-
ically and unpredictably over coming years. For 
the present, the ICMJE will not consider results 
posted in the same primary clinical trials register 
in which the initial registration resides as previ-
ous publications if the results are presented in the 
form of a brief, structured (<500 words) abstract 
or table. The ICMJE favors a standard abstract 
format for results reporting, and the CON-
SORT (Consolidated Standards for the Report-
ing of Trials) group’s forthcoming guidelines for 
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abstracts related to trials may be one such option. 
The ICMJE believes that parties interested in re-
sults registration should consider requiring the 
deposition of such an abstract in the registry 24 
months after closure of data collection if results 
are not published in a peer-reviewed venue by 
that time. The registered abstract should either 
cite any related full, peer-reviewed publications 
or include a statement that indicates that the 
report has not yet been published in a peer-re-
viewed journal. Researchers should be aware that 
editors may consider more detailed deposition of 
trial results in publicly available registries to be 
prior publication. When submitting a paper, au-
thors should fully disclose to editors all posting 
in registries of results of the same or closely relat-
ed work.
Three years ago, trials registration was the ex-
ception; now it is the rule. Registration facilitates 
the dissemination of information among clini-
cians, researchers, and patients, and it helps to as-
sure trial participants that the information that 
accrues as a result of their altruism will become 
part of the public record. The WHO’s global ef-
forts towards comprehensive trials registration 
and the ICMJE’s requirements for registration 
aim to increase public trust in medical science.
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